BCAB SEC Filings: 8-K, 10-Q, S-3 & 424B – BioAtla

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Apr 29, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Company Secures $40 Million Standby Equity Facility and Issues Warrants to Yorkville for Initial Commitment Fee Payment

Oct 19, 2026

8-K

BioAtla Announces Executive Departures, Consulting Agreements, and Reinstated Retention and Performance Bonuses

Sep 29, 2026

8-K

BioAtla, Inc. Receives Notice of Delisting from Nasdaq

Aug 28, 2026

8-K

BioAtla, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jul 16, 2026

8-K

BioAtla, Inc. Files Certificate of Merger

Apr 2, 2026

8-K

BioAtla Initiates Strategic Review Process and Implements Cost-Reduction Measures

Mar 31, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Oct 29, 2026

424B2

SPA | Offering amount: $151,000 | Shares: 842,440 | Price: $0.179

Mar 20, 2026

424B2

SPA | Offering amount: $108,000 | Shares: 631,163 | Price: $0.171

Mar 13, 2026

424B2

SPA | Offering amount: $154,000 | Shares: 931,032 | Price: $0.166

Mar 6, 2026

424B5

SPA

Nov 21, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 9,679,158

May 16, 2025

Registrations

TYPE

HEADLINE

FILED AT

Form RW - Registration Withdrawal Request

Oct 27, 2026

S-1

YA II PN, Ltd. - SPA - 97% of the lowest daily VWAP over 3 trading days starting on the notice date. Up to 100% of the prior 5-day average daily volume per Advance; daily Advance count not specified. No fixed floor; company-set minimum optional; 4.99% ownership cap. EFFECTIVE, DATED 2026-10-29

Oct 19, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 31, 2026

S-3

January 2026 SHELF

Jan 16, 2026

S-3

SHARE RESALE REGISTRATION | Shares amount: 9,679,158 | Warrants amount: 9,679,158

May 6, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 28, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 3, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jun 3, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 2, 2026

DEFM14A

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Feb 11, 2026

PREM14A

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Jan 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jan 15, 2026

Ownerships

TYPE

HEADLINE

FILED AT

Sievers Eric (Reporting)

Sep 2, 2026

SHORT JAY M PHD (Reporting)

Sep 2, 2026

Vasquez Christian (Reporting)

Sep 2, 2026

Vasquez Christian (Reporting)

Jun 5, 2026

Sievers Eric (Reporting)

Jun 5, 2026

SHORT JAY M PHD (Reporting)

Jun 5, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 30, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

May 15, 2025

CORRESP

Form CORRESP - Correspondence

May 12, 2025

LETTER

Form UPLOAD - SEC-generated letter

May 9, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 18, 2023

CORRESP

Form CORRESP - Correspondence

Jan 13, 2023

BioAtla, Inc. BCAB · SEC Filings